A prognostic test to guide adjuvant chemotherapy (ACT) decisions in early-stage non-small cell lung cancer (NSCLC): A cost-effectiveness analysis.

被引：0
|
作者：
Stenehjem, David D.
Bellows, Brandon Kyle
Kaldate, Rajesh R.
Jones, Joshua Timothy
Siebert, Uwe
Brixner, Diana I.
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT USA
[3] Myriad Genet Labs Inc, Salt Lake City, UT USA
[4] Myriad Genet Inc, Salt Lake City, UT USA
[5] Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[6] Univ Utah, LS Skaggs Pharm Inst, Salt Lake City, UT USA
[7] Univ Utah, Program Personalized Hlth Care, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e18509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18509
引用
收藏
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF USING A PROGNOSTIC TEST TO GUIDE TREATMENT DECISIONS IN EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
    Stenehjem, D.
    Bellows, B. K.
    Kaldate, R. R.
    Jones, J.
    Siebert, U.
    Brixner, D.
    VALUE IN HEALTH, 2014, 17 (03) : A89 - A89
  • [2] Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer
    Stenehjem, David D.
    Bellows, Brandon K.
    Yager, Kraig M.
    Jones, Joshua
    Kaldate, Rajesh
    Siebert, Uwe
    Brixner, Diana I.
    ONCOLOGIST, 2016, 21 (02): : 196 - 204
  • [3] The role of adjuvant chemotherapy in stage IB non-small cell lung cancer: A decision, effectiveness, and cost-effectiveness analysis.
    Hudson, Jessica Lynn
    Aung, Wint Y.
    Santos, Carlos A. Q.
    Chang, Su-Hsin
    Olsen, Margaret A.
    Meyers, Bryan F.
    Morgensztern, Daniel
    Puri, Varun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Adjuvant chemotherapy for early-stage non-small cell lung cancer
    Visbal, AL
    Leighl, NB
    Feld, R
    Shepherd, FA
    CHEST, 2005, 128 (04) : 2933 - 2943
  • [5] Adjuvant chemotherapy in early-stage non-small cell lung cancer
    Dômont, J
    Soria, JC
    Le Chevalier, T
    SEMINARS IN ONCOLOGY, 2005, 32 (03) : 279 - 283
  • [6] Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
    Tian, Wentao
    Niu, Lishui
    Wang, Ziqi
    Lu, Ruoyu
    Xiao, Gang
    Deng, Fuxing
    Tanzhu, Guilong
    Zhou, Rongrong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [7] Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
    Burdett, Sarah
    Pignon, Jean Pierre
    Tierney, Jayne
    Tribodet, Helene
    Stewart, Lesley
    Le Pechoux, Cecile
    Auperin, Anne
    Le Chevalier, Thierry
    Stephens, Richard J.
    Arriagada, Rodrigo
    Higgins, Julian P. T.
    Johnson, David H.
    Van Meerbeeck, Jan
    Parmar, Mahesh K. B.
    Souhami, Robert L.
    Bergman, Bengt
    Douillard, Jean-Yves
    Dunant, Ariane
    Endo, Chiaki
    Girling, David
    Kato, Harubumi
    Keller, Steven M.
    Kimura, Hideki
    Knuuttila, Aija
    Kodama, Ken
    Komaki, Ritsuko
    Kris, Mark G.
    Lad, Thomas
    Mineo, Tommaso
    Piantadosi, Steven
    Rosell, Rafael
    Scagliotti, Giorgio
    Seymour, Lesley K.
    Shepherd, Frances A.
    Sylvester, Richard
    Tada, Hirohito
    Tanaka, Fumihiro
    Torri, Valter
    Waller, David
    Liang, Ying
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (03):
  • [8] Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer
    Inamura, Kentaro
    JAMA ONCOLOGY, 2021, 7 (04) : 637 - 638
  • [9] Adjuvant Chemotherapy in Elderly Patients with Early-stage Non-small Cell Lung Cancer
    Kefeli, Umut
    Kaymaz, Samet
    Aydin, Dincer
    Isik, Deniz
    Cabuk, Devrim
    Sonkaya, Alper
    Acikgoz, Ozgur
    Isik, Ulas
    Ozden, Ercan
    Uygun, Kazim
    BEZMIALEM SCIENCE, 2019, 7 (04): : 265 - 270
  • [10] Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer Reply
    Pathak, Ranjan
    Boffa, Daniel J.
    JAMA ONCOLOGY, 2021, 7 (04) : 638 - 638
12345